FGEN
Price:
$8.25
Market Cap:
$33.37M
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopath...[Read more]
Industry
Biotechnology
IPO Date
2014-11-14
Stock Exchange
NASDAQ
Ticker
FGEN
According to FibroGen, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 103.14M. This represents a change of -87.20% compared to the average of 805.87M of the last 4 quarters.
The mean historical Enterprise Value of FibroGen, Inc. over the last ten years is 51.16B. The current 103.14M Enterprise Value has changed -79.84% with respect to the historical average. Over the past ten years (40 quarters), FGEN's Enterprise Value was at its highest in in the June 2018 quarter at 130.36B. The Enterprise Value was at its lowest in in the June 2025 quarter at 91.19M.
Average
51.16B
Median
41.66B
Minimum
1.35B
Maximum
97.27B
Discovering the peaks and valleys of FibroGen, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 156.52%
Maximum Annual Enterprise Value = 97.27B
Minimum Annual Increase = -94.09%
Minimum Annual Enterprise Value = 1.35B
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 1.35B | -39.12% |
| 2023 | 2.21B | -94.09% |
| 2022 | 37.41B | 15.12% |
| 2021 | 32.50B | -60.70% |
| 2020 | 82.70B | -10.90% |
| 2019 | 92.82B | -4.58% |
| 2018 | 97.27B | 13.22% |
| 2017 | 85.91B | 156.52% |
| 2016 | 33.49B | -27.04% |
| 2015 | 45.91B | 17.14% |
The current Enterprise Value of FibroGen, Inc. (FGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
13.66B
5-year avg
31.23B
10-year avg
51.16B
FibroGen, Inc.’s Enterprise Value is greater than Kezar Life Sciences, Inc. (20.85M), greater than Tempest Therapeutics, Inc. (9.57M), greater than Aligos Therapeutics, Inc. (26.21M), greater than OnKure Therapeutics, Inc. (-34012234.00), greater than Mersana Therapeutics, Inc. (83.22M), greater than X4 Pharmaceuticals, Inc. (6.31M), greater than PDS Biotechnology Corporation (-26077209422.00), less than Celularity Inc. (112.66M), greater than Xilio Therapeutics, Inc. (-57598257.00), greater than Actinium Pharmaceuticals, Inc. (-7013958.00),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 20.85M | $45.77M | |
| 9.57M | $15.19M | |
| 26.21M | $62.09M | |
| -34012234.00 | $35.63M | |
| 83.22M | $137.32M | |
| 6.31M | $43.35M | |
| -26077209422.00 | $43.78M | |
| 112.66M | $47.46M | |
| -57598257.00 | $38.90M | |
| -7013958.00 | $45.23M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like FibroGen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like FibroGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is FibroGen, Inc.'s Enterprise Value?
What is the highest Enterprise Value for FibroGen, Inc. (FGEN)?
What is the 3-year average Enterprise Value for FibroGen, Inc. (FGEN)?
What is the 5-year average Enterprise Value for FibroGen, Inc. (FGEN)?
How does the current Enterprise Value for FibroGen, Inc. (FGEN) compare to its historical average?